BRTX prices $2.1M registered direct offering of 685,033 shares at $3.03/share

BioRestorative Therapies, Inc.

Offering of 685,033 shares at $3.03/share for gross proceeds of approximately $2.1M; closing expected July 13, 2023.
Net proceeds to fund BRTX-100 clinical trials, ThermoStem Program R&D, and general corporate purposes.
Titan Partners Group acting as sole placement agent with 6% cash fee and up to $60K expense reimbursement.
Shares offered under effective S-3 shelf registration (File No. 333-269631).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BioRestorative Therapies, Inc. entered into Placement Agency Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC (effective 2023-07-11).

Action: entry
Agreement: underwriting
Counterparty: Titan Partners Group LLC, a division of American Capital Partners, LLC
Effective: 2023-07-11

Exact text from the filing

the Company entered into a placement agency agreement dated July 11, 2023 (the “Placement Agency Agreement”), with Titan Partners Group LLC, a division of American Capital Partners, LLC

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BioRestorative Therapies, Inc. entered into Purchase Agreement with several institutional buyers and accredited investors valued at approximately $2.1 million (effective 2023-07-11).

Action: entry
Agreement: equity purchase
Counterparty: several institutional buyers and accredited investors
Value: approximately $2.1 million
Effective: 2023-07-11

Exact text from the filing

On July 11, 2023, BioRestorative Therapies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with several institutional buyers and accredited investors (the “Purchasers”)

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

BioRestorative Therapies, Inc. filing history →

Source: SEC EDGAR

accession 0001021771-23-000057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.